Michael Arad
YOU?
Author Swipe
View article: Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM
Mavacamten Monotherapy in Real-World Patients with Obstructive Hypertrophic Cardiomyopathy: Evidence From COLLIGO-HCM Open
Background: Mavacamten has been shown to improve cardiac function and symptoms in patients with symptomatic (New York Heart Association [NYHA] class II-III) obstructive hypertrophic cardiomyopathy (HCM). Clinical studies suggest mavacamten…
View article: Improved Survival in Octogenarians With Heart Failure
Improved Survival in Octogenarians With Heart Failure Open
Over a 15-year period, mortality risks among octogenarians and older with HF decreased, especially in HFpEF and nonfrail patients.
View article: Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy
Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy Open
View article: Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial
Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial Open
Background and Aims Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity. This analysis explores whether oHCM a…
View article: Hereditary Transthyretin Amyloidosis in Israel: Genetic Landscape and Clinical Characteristics
Hereditary Transthyretin Amyloidosis in Israel: Genetic Landscape and Clinical Characteristics Open
Background Hereditary transthyretin (ATTRv) amyloidosis is a rare, adult‐onset autosomal‐dominant disorder caused by pathogenic variants in the transthyretin ( TTR ) gene. Data about relevant variants in specific populations and typical in…
View article: Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy Open
View article: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA‐HCM Open
Background Aficamten, a novel cardiac myosin inhibitor, reversibly reduces cardiac hypercontractility in obstructive hypertrophic cardiomyopathy. We present a prespecified analysis of the pharmacokinetics, pharmacodynamics, and safety of a…
View article: Pericarditis recurrence is associated with milder electrocardiographic, echocardiographic, and laboratory findings
Pericarditis recurrence is associated with milder electrocardiographic, echocardiographic, and laboratory findings Open
Recurrent pericarditis (RP) complicates approximately 30% of acute pericarditis (AP) cases. We sought to compare the prevalence and severity of objective findings seen in patients with RP. A retrospective single-center study during 2010–20…
View article: Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept
Sustained Pericarditis Recurrence Risk Reduction With Long‐Term Rilonacept Open
Background Rilonacept, a once‐weekly interleukin‐1 alpha and beta cytokine trap, reduced pericarditis recurrence in the phase 3 study, RHAPSODY (Rilonacept Inhibition of Interleukin‐1 Alpha and Beta for Recurrent Pericarditis: A Pivotal Sy…
View article: Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension
Absence of Pericarditis Recurrence in Rilonacept-Treated Patients With COVID-19 and SARS-CoV-2 Vaccination: Results From the RHAPSODY Long-term Extension Open
View article: Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy
Exercise Capacity in Patients With Obstructive Hypertrophic Cardiomyopathy Open
Patients with obstructive hypertrophic cardiomyopathy (oHCM) have increased risk of arrhythmia, stroke, heart failure, and sudden death. Contemporary management of oHCM has decreased annual hospitalization and mortality rates, yet patients…
View article: Myocardial edema measured by T2 mapping is an independent predictor of ventricular arrhythmias in hypertrophic cardiomyopathy
Myocardial edema measured by T2 mapping is an independent predictor of ventricular arrhythmias in hypertrophic cardiomyopathy Open
Introduction Clinical outcome of patients with hypertrophic cardiomyopathy (HCM) largely depends on ventricular arrhythmias. Parametric T2 mapping from Cardiac MRI (CMR) was found to be a measure of myocardial edema. We sought to study whe…
View article: International Consensus on Differential Diagnosis and Management of Patients With Danon Disease
International Consensus on Differential Diagnosis and Management of Patients With Danon Disease Open
Danon disease is a rare X-linked autophagic vacuolar cardioskeletal myopathy associated with severe heart failure that can be accompanied with extracardiac neurologic, skeletal, and ophthalmologic manifestations. It is caused by loss of fu…
View article: Reply to Kataoka, N.; Imamura, T. How to Improve Clinical Outcomes in Patients with Tachycardia-Induced Cardiomyopathy. Comment on “Katz et al. Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy. J. Clin. Med. 2023, 12, 1412”
Reply to Kataoka, N.; Imamura, T. How to Improve Clinical Outcomes in Patients with Tachycardia-Induced Cardiomyopathy. Comment on “Katz et al. Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy. J. Clin. Med. 2023, 12, 1412” Open
In a letter to the editor titled “How to improve clinical outcomes in patients with tachycardia-induced cardiomyopathy”, Dr. Naoya Kataoka and Dr. Teruhiko Imamura [...]
View article: 2023 ESC Guidelines for the management of cardiomyopathies
2023 ESC Guidelines for the management of cardiomyopathies Open
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. Guidelines are intended for use …
View article: Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis
Pericardial late gadolinium enhancement and time to recurrence: a substudy from RHAPSODY, a phase 3 clinical trial of rilonacept in recurrent pericarditis Open
Aims In this protocol-predefined substudy of the RHAPSODY trial, the primary aim was to assess whether pericardial late gadolinium enhancement (LGE) was associated with time to pericarditis recurrence. Methods and results RHAPSODY was a Ph…
View article: Diagnostic Challenges and Solutions in Systemic Amyloidosis
Diagnostic Challenges and Solutions in Systemic Amyloidosis Open
Amyloidosis refers to a clinically heterogeneous group of disorders characterized by the extracellular deposition of amyloid proteins in various tissues of the body. To date, 42 different amyloid proteins that originate from normal precurs…
View article: <scp>Ser77Tyr</scp> transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features
<span>Ser77Tyr</span> transthyretin amyloidosis in Israel: Initial manifestations and diagnostic features Open
Objective Amyloidosis due to the transthyretin Ser77Tyr mutation (ATTRS77Y) is a rare autosomal‐dominant disorder, characterized by carpal‐tunnel syndrome, poly‐ and autonomic‐neuropathy, and cardiomyopathy. However, related symptoms and s…
View article: Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy
Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy Open
Background: data on the natural course and prognosis of tachycardia-induced cardiomyopathy (TICMP) and comparison with idiopathic dilated cardiomyopathies (IDCM) are scarce. Objective: To compare the clinical presentation, comorbidities, a…
View article: Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY
Interleukin‐1 Trap Rilonacept Improved Health‐Related Quality of Life and Sleep in Patients With Recurrent Pericarditis: Results From the Phase 3 Clinical Trial RHAPSODY Open
Background Recurrent pericarditis is characterized by painful flares and inflammation, which negatively impact health‐related quality of life. RHAPSODY (rilonacept inhibition of interleukin‐1 alpha and beta for recurrent pericarditis: a pi…
View article: Silencing the Adipocytokine NOV: A Novel Approach to Reversing Oxidative Stress-Induced Cardiometabolic Dysfunction
Silencing the Adipocytokine NOV: A Novel Approach to Reversing Oxidative Stress-Induced Cardiometabolic Dysfunction Open
Objective: NOV/CCN3 is an adipocytokine recently linked to obesity, insulin resistance, and cardiometabolic dysfunction. NOV is manufactured and secreted from adipose tissue, with blood levels highly correlated with BMI. NOV levels are inc…
View article: Contemporary outcome of subsequent pregnancies in patients with previous peripartum cardiomyopathy
Contemporary outcome of subsequent pregnancies in patients with previous peripartum cardiomyopathy Open
Aims To describe the effect of subsequent pregnancies (SSP) on left ventricular (LV) function and outcomes in patients with peripartum cardiomyopathy (PPCM). Methods Among146 women with PPCM who were prospectively followed at two medical c…
View article: Bioenergetic and Metabolic Impairments in Induced Pluripotent Stem Cell-Derived Cardiomyocytes Generated from Duchenne Muscular Dystrophy Patients
Bioenergetic and Metabolic Impairments in Induced Pluripotent Stem Cell-Derived Cardiomyocytes Generated from Duchenne Muscular Dystrophy Patients Open
Duchenne muscular dystrophy (DMD) is caused by mutations in the dystrophin gene and dilated cardiomyopathy (DCM) is a major cause of morbidity and mortality in DMD patients. We tested the hypothesis that DCM is caused by metabolic impairme…
View article: The Prognostic Role of Mitral Valve Regurgitation Severity and Left Ventricle Function in Acute Heart Failure
The Prognostic Role of Mitral Valve Regurgitation Severity and Left Ventricle Function in Acute Heart Failure Open
Aims: Data about the prognostic interplay between mitral regurgitation MR and left ventricular (LV) function in the outcome of patients admitted with acute heart failure (AHF) are scarce. We evaluated the prognostic impact of MR severity a…
View article: The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine
The clinical course of patients with previous acute and recurrent pericarditis receiving the BNT162b2 vaccine Open
View article: Adipocyte-Specific Expression of PGC1α Promotes Adipocyte Browning and Alleviates Obesity-Induced Metabolic Dysfunction in an HO-1-Dependent Fashion
Adipocyte-Specific Expression of PGC1α Promotes Adipocyte Browning and Alleviates Obesity-Induced Metabolic Dysfunction in an HO-1-Dependent Fashion Open
Recent studies suggest that PGC1-α plays a crucial role in mitochondrial and vascular function, yet the physiological significance of PGC1α and HO expression in adipose tissues in the context of obesity-linked vascular dysfunction remains …
View article: SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients
SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients Open
Background: Patients with cardiomyopathy of Duchenne Muscular Dystrophy (DMD) are at risk of developing life-threatening arrhythmias, but the mechanisms are unknown. We aimed to determine the role of ion channels controlling cardiac excita…
View article: Author response: SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients
Author response: SNTA1 gene rescues ion channel function and is antiarrhythmic in cardiomyocytes derived from induced pluripotent stem cells from muscular dystrophy patients Open
Article Figures and data Abstract Editor's evaluation Introduction Methods Results Discussion Appendix 1 Data availability References Decision letter Author response Article and author information Metrics Abstract Background: Patients with…
View article: Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis
Hypokinetic hypertrophic cardiomyopathy: clinical phenotype, genetics, and prognosis Open
Aims To describe the phenotype, genetics, and events associated with the development of hypertrophic cardiomyopathy (HCM) with reduced ventricular function (HCMr). Heart failure in HCM is usually associated with preserved ejection fraction…
View article: THE CLINICAL COURSE OF PATIENTS WITH A HISTORY OF ACUTE PERICARDITIS FOLLOWING VACCINATION AGAINST SARS-COV2
THE CLINICAL COURSE OF PATIENTS WITH A HISTORY OF ACUTE PERICARDITIS FOLLOWING VACCINATION AGAINST SARS-COV2 Open